vs
Apellis Pharmaceuticals, Inc.（APLS）与BJs RESTAURANTS INC（BJRI）财务数据对比。点击上方公司名可切换其他公司
BJs RESTAURANTS INC的季度营收约是Apellis Pharmaceuticals, Inc.的1.8倍（$355.4M vs $199.9M），BJs RESTAURANTS INC净利率更高（3.6% vs -29.5%，领先33.0%），BJs RESTAURANTS INC同比增速更快（3.2% vs -5.9%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 2.6%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
BJ's Restaurants Inc.是美国休闲连锁餐饮企业，旗下门店遍布美国多个地区，主打招牌深盘披萨、精酿啤酒、手工鸡尾酒及各类美式家常餐食，服务家庭聚餐、朋友聚会等多元客群，主打轻松舒适的用餐氛围。
APLS vs BJRI — 直观对比
营收规模更大
BJRI
是对方的1.8倍
$199.9M
营收增速更快
BJRI
高出9.1%
-5.9%
净利率更高
BJRI
高出33.0%
-29.5%
两年增速更快
APLS
近两年复合增速
2.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $355.4M |
| 净利润 | $-59.0M | $12.6M |
| 毛利率 | — | 74.5% |
| 营业利润率 | -25.6% | 3.1% |
| 净利率 | -29.5% | 3.6% |
| 营收同比 | -5.9% | 3.2% |
| 净利润同比 | -62.2% | -24.2% |
| 每股收益（稀释后） | $-0.40 | $0.58 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSBJRI
| Q4 25 | $199.9M | $355.4M | ||
| Q3 25 | $458.6M | $365.6M | ||
| Q2 25 | $178.5M | $348.0M | ||
| Q1 25 | $166.8M | — | ||
| Q4 24 | $212.5M | $325.7M | ||
| Q3 24 | $196.8M | $349.9M | ||
| Q2 24 | $199.7M | $337.3M | ||
| Q1 24 | $172.3M | — |
净利润APLSBJRI
| Q4 25 | $-59.0M | $12.6M | ||
| Q3 25 | $215.7M | $22.2M | ||
| Q2 25 | $-42.2M | $13.5M | ||
| Q1 25 | $-92.2M | — | ||
| Q4 24 | $-36.4M | $-2.9M | ||
| Q3 24 | $-57.4M | $17.2M | ||
| Q2 24 | $-37.7M | $7.7M | ||
| Q1 24 | $-66.4M | — |
毛利率APLSBJRI
| Q4 25 | — | 74.5% | ||
| Q3 25 | — | 75.2% | ||
| Q2 25 | — | 75.0% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 73.4% | ||
| Q3 24 | — | 74.3% | ||
| Q2 24 | — | 74.8% | ||
| Q1 24 | — | — |
营业利润率APLSBJRI
| Q4 25 | -25.6% | 3.1% | ||
| Q3 25 | 48.7% | 5.8% | ||
| Q2 25 | -18.6% | 4.3% | ||
| Q1 25 | -50.0% | — | ||
| Q4 24 | -12.3% | -0.8% | ||
| Q3 24 | -24.0% | 3.8% | ||
| Q2 24 | -14.7% | 2.4% | ||
| Q1 24 | -36.0% | — |
净利率APLSBJRI
| Q4 25 | -29.5% | 3.6% | ||
| Q3 25 | 47.0% | 6.1% | ||
| Q2 25 | -23.6% | 3.9% | ||
| Q1 25 | -55.3% | — | ||
| Q4 24 | -17.1% | -0.9% | ||
| Q3 24 | -29.2% | 4.9% | ||
| Q2 24 | -18.9% | 2.3% | ||
| Q1 24 | -38.5% | — |
每股收益（稀释后）APLSBJRI
| Q4 25 | $-0.40 | $0.58 | ||
| Q3 25 | $1.67 | $0.97 | ||
| Q2 25 | $-0.33 | $0.58 | ||
| Q1 25 | $-0.74 | — | ||
| Q4 24 | $-0.30 | $-0.13 | ||
| Q3 24 | $-0.46 | $0.72 | ||
| Q2 24 | $-0.30 | $0.32 | ||
| Q1 24 | $-0.54 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $23.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $366.2M |
| 总资产 | $1.1B | $1.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSBJRI
| Q4 25 | $466.2M | $23.8M | ||
| Q3 25 | $479.2M | $26.0M | ||
| Q2 25 | $370.0M | $19.0M | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | $18.4M | ||
| Q3 24 | $396.9M | $16.2M | ||
| Q2 24 | $360.1M | $18.8M | ||
| Q1 24 | $325.9M | — |
总债务APLSBJRI
| Q4 25 | — | — | ||
| Q3 25 | — | $60.5M | ||
| Q2 25 | — | $85.5M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $66.5M | ||
| Q3 24 | — | $63.5M | ||
| Q2 24 | — | $58.0M | ||
| Q1 24 | $93.1M | — |
股东权益APLSBJRI
| Q4 25 | $370.1M | $366.2M | ||
| Q3 25 | $401.2M | $386.6M | ||
| Q2 25 | $156.3M | $371.5M | ||
| Q1 25 | $164.2M | — | ||
| Q4 24 | $228.5M | $376.2M | ||
| Q3 24 | $237.1M | $386.5M | ||
| Q2 24 | $264.3M | $375.4M | ||
| Q1 24 | $266.7M | — |
总资产APLSBJRI
| Q4 25 | $1.1B | $1.0B | ||
| Q3 25 | $1.1B | $1.0B | ||
| Q2 25 | $821.4M | $1.0B | ||
| Q1 25 | $807.3M | — | ||
| Q4 24 | $885.1M | $1.0B | ||
| Q3 24 | $901.9M | $1.0B | ||
| Q2 24 | $904.5M | $1.0B | ||
| Q1 24 | $831.9M | — |
负债/权益比APLSBJRI
| Q4 25 | — | — | ||
| Q3 25 | — | 0.16× | ||
| Q2 25 | — | 0.23× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSBJRI
| Q4 25 | $-14.2M | — | ||
| Q3 25 | $108.5M | $62.3M | ||
| Q2 25 | $4.4M | $4.6M | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.4M | $27.3M | ||
| Q3 24 | $34.1M | $20.2M | ||
| Q2 24 | $-8.3M | $22.3M | ||
| Q1 24 | $-133.0M | — |
自由现金流APLSBJRI
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | $41.9M | ||
| Q2 25 | $4.4M | $-12.1M | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | $7.6M | ||
| Q3 24 | — | $735.0K | ||
| Q2 24 | $-8.4M | $448.0K | ||
| Q1 24 | $-133.3M | — |
自由现金流率APLSBJRI
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | 11.5% | ||
| Q2 25 | 2.5% | -3.5% | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | 2.3% | ||
| Q3 24 | — | 0.2% | ||
| Q2 24 | -4.2% | 0.1% | ||
| Q1 24 | -77.3% | — |
资本支出强度APLSBJRI
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | 5.6% | ||
| Q2 25 | 0.0% | 4.8% | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | 6.0% | ||
| Q3 24 | 0.0% | 5.6% | ||
| Q2 24 | 0.0% | 6.5% | ||
| Q1 24 | 0.2% | — |
现金转化率APLSBJRI
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 2.80× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.18× | ||
| Q2 24 | — | 2.89× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
BJRI
暂无分部数据
